Becton, Dickinson and Company $BDX Shares Purchased by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH raised its position in Becton, Dickinson and Company (NYSE:BDX) by 3.2% in the 1st quarter, Holdings Channel reports. The fund owned 981,876 shares of the medical instruments supplier’s stock after purchasing an additional 30,420 shares during the period. Becton, Dickinson and Company accounts for 0.9% of Fort Washington Investment Advisors Inc. OH’s holdings, making the stock its 26th biggest holding. Fort Washington Investment Advisors Inc. OH’s holdings in Becton, Dickinson and Company were worth $154,380,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Value Partners Investments Inc. lifted its position in shares of Becton, Dickinson and Company by 34.7% during the first quarter. Value Partners Investments Inc. now owns 7,544 shares of the medical instruments supplier’s stock worth $1,186,000 after purchasing an additional 1,944 shares in the last quarter. Venturi Wealth Management LLC boosted its position in Becton, Dickinson and Company by 14.4% in the 1st quarter. Venturi Wealth Management LLC now owns 1,458 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 184 shares during the last quarter. HF Advisory Group LLC grew its stake in shares of Becton, Dickinson and Company by 70.5% during the first quarter. HF Advisory Group LLC now owns 9,666 shares of the medical instruments supplier’s stock valued at $1,520,000 after acquiring an additional 3,996 shares in the last quarter. Poehling Capital Management INC. increased its position in shares of Becton, Dickinson and Company by 12.5% during the first quarter. Poehling Capital Management INC. now owns 9,290 shares of the medical instruments supplier’s stock worth $1,461,000 after acquiring an additional 1,035 shares during the last quarter. Finally, Grey Ledge Advisors LLC increased its position in shares of Becton, Dickinson and Company by 20.9% during the first quarter. Grey Ledge Advisors LLC now owns 2,800 shares of the medical instruments supplier’s stock worth $440,000 after acquiring an additional 484 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on BDX. Evercore increased their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research note on Tuesday, April 14th. The Goldman Sachs Group decreased their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $181.00.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,188 shares of company stock valued at $765,120 over the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 3.1%

BDX stock opened at $156.06 on Friday. The firm has a market cap of $43.00 billion, a price-to-earnings ratio of 39.51, a PEG ratio of 11.04 and a beta of 0.22. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The firm has a fifty day moving average price of $148.17 and a two-hundred day moving average price of $170.75. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same period last year, the firm posted $3.35 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.